The objective of this trial was to evaluate whether Org 36286 treatment in any Phase IIa clinical development trial of Org 36286 for OI or COH in assisted reproductive treatment programs was safe for pregnant subjects and their offspring. Data from subjects who participated in Trials 38805 and 38807 and became pregnant were evaluated.

This was an open prospective follow-up trial to monitor pregnancy, delivery, and neonatal outcome of women who became pregnant during any Phase IIa clinical trial of Org 36286 for OI or COH for IVF. For this trial, no study specific assessments were required, but information obtained in standard practice was used.

Inclusion Criteria:

• Subjects taking part in any clinical development trial of Org 36286 for OI or COH for IVF in Phase IIa;
• Ongoing pregnancy confirmed by ultrasonography (USS) at or beyond 12 weeks of gestation;
• Able and willing to give written informed consent.

Exclusion Criteria:

• None

All women who became pregnant during Trials 38805 or 38807 were enrolled in Trial 38817